Paediatric Psoriasis Virtual Symposium
EADV Virtual 2020: Paediatric Psoriasis - Full clearance can be up to you
Register your interest in this EACCME™ accredited* independently led symposium that brings together leading experts in the field of psoriasis: Professors Amy Paller, Tiago Torres and Marieke Seyger.
*This live educational event is currently under consideration for accreditation with EACCME.
By clicking the "Sign Up" button you confirm you are happy to receive further information about this live symposium
Virtual Symposium Agenda
| Paediatric Psoriasis - Full clearance can be up to you Friday, 30th October 2020, 13:00-14:00 CET |
||
| Chair: Amy Paller | ||
| 13:00 | Welcome address | Amy Paller (US) |
| 13:05 | The dangers of undertreatment in paediatric psoriasis | Marieke Seyger (NL) |
| 13:20 | What is playing it safe in paediatric psoriasis? | Tiago Torres (PT) |
| 13:35 | PASI 75 is not enough | Amy Paller (US) |
| 13:50 | Panel discussion and live questions | All speakers |
Following the journey of Mia, Marieke Seyger will share the importance of early and effective disease control as well as the particular burden of disease for children and adolescents with moderate-to-severe psoriasis and the lack of treatment options compared with adults.
Tiago Torres will discuss the safety profile of modern biologic and traditional systemic treatments and also share safety data on more recently approved biologics such as IL-17 inhibitors.
You also won’t want to miss Amy Paller discussing the impact of psoriasis on patient quality of life and the need to aim higher than PASI 75 for paediatric patients. She will also discuss the latest efficacy data for currently approved biologics and review the current clinical trial landscape.
There will also be an engaging panel discussion with all the speakers and the opportunity to ask your key questions during the live Q&A session.
Add event to calendar
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.